What is the Fractyl Health securities class action lawsuit about?

The lawsuit alleges that Fractyl Health, Inc. (NASDAQ: GUTS) made false and/or misleading statements to investors regarding its Revita treatment during the class period of January 13, 2025 to January 29, 2026. Specifically, the complaint alleges that Defendants overstated Revita's clinical, regulatory, and commercial prospects while failing to disclose that the treatment was less effective than represented and that operational issues at certain clinical sites allegedly compromised the integrity of the REMAIN-1 Midpoint Cohort's efficacy results.

Who can join the Fractyl Health GUTS stock class action?

Investors who purchased or acquired Fractyl Health securities between January 13, 2025 and January 29, 2026 may be eligible to participate in the class action. If you suffered losses on your Fractyl Health investment during this period, you may have legal rights worth exploring with a securities attorney.

What is the lead plaintiff deadline for the Fractyl Health lawsuit?

The deadline to apply for lead plaintiff in the Fractyl Health securities class action is October 20, 2026. Investors who wish to seek appointment as lead plaintiff must file their motion with the U.S. District Court for the Southern District of New York by that date.

What did Fractyl Health allegedly misrepresent about Revita?

The complaint alleges that Defendants misled investors by overstating Revita's effectiveness and its clinical, regulatory, and commercial prospects. The lawsuit further alleges that Defendants failed to disclose that operational issues at one or more REMAIN-1 Midpoint Cohort clinical sites allegedly compromised the integrity of the trial's efficacy results, rendering Defendants' public statements materially false and misleading.

What is the REMAIN-1 Midpoint Cohort and why does it matter to the Fractyl Health case?

The REMAIN-1 Midpoint Cohort refers to a clinical trial cohort used to evaluate the efficacy of Fractyl Health's Revita treatment. The lawsuit alleges that operational issues at one or more of the cohort's clinical sites undermined the integrity of its efficacy data, and that Defendants nonetheless made public statements that overstated the cohort's ability to reliably assess Revita's effectiveness.

In which court was the Fractyl Health securities lawsuit filed?

The Fractyl Health securities class action has been filed in the U.S. District Court for the Southern District of New York. This federal court is a common venue for securities fraud class action litigation.

Do I need to have sold my Fractyl Health stock to be part of the class action?

You do not necessarily need to have sold your shares to potentially participate in the class action; eligibility is generally based on having purchased or acquired Fractyl Health securities during the class period of January 13, 2025 to January 29, 2026. You should consult a qualified securities attorney to evaluate your specific situation and potential losses.

What happens if I miss the October 2026 lead plaintiff deadline in the Fractyl Health case?

Missing the October 20, 2026 lead plaintiff deadline means you cannot apply to serve as the representative plaintiff who helps direct the litigation on behalf of the class. However, you may still be able to participate as a class member and potentially recover damages if the case is successful, so it is worth consulting an attorney about your options.

Fractyl Health, Inc. - Faruqi & Faruqi LLP

Fractyl Health, Inc.

Join Action

Case Details

Ticker GUTS

Class Period 01/13/2025 - 01/29/2026

Lead Plaintiff Deadline 10/20/2026

Days Left to Seek Lead Plaintiff

If you are a Fractyl Health, Inc. investor who suffered a loss and would like to learn more, you can provide your information below:

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Fractyl Health To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Fractyl Health between January 13, 2025 and January 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Fractyl Health, Inc. (“Fractyl Health” or the “Company”) (NASDAQ: GUTS) and reminds investors of the October 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Revita was less effective than Defendants had led investors to believe, and/or operational issues at one or more of the REMAIN-1 Midpoint Cohort’s clinical sites compromised the integrity of its efficacy results; (ii) accordingly, Revita’s clinical, regulatory, and commercial prospects were overstated, as was the REMAIN-1 Midpoint Cohort’s ability to assess Revita’s efficacy; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Lead Plaintiff Deadline: October 20, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). Or submit your information below to learn about your rights.

Join Action

Fractyl Health, Inc.

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify